"We look forward to a decision from the MHLW, which, if positive, would provide a new therapeutic option for appropriate patients with COPD in Japan," said Dr Ted Witek, the senior vice president and chief scientific officer at Innoviva
More From BioPortfolio on "Glaxo makes new drug application in Japan for COPD treatment, Trelegy Ellipta"